Summary of findings 3. IPV(3)‐OPV compared to IPV(2)‐OPV for preventing poliomyelitis.
| 3 IPV‐OPV compared to 2 IPV‐OPV for preventing poliomyelitis | ||||||
| Patient or population: preventing poliomyelitis Setting: India Intervention: 3 IPV‐OPV Comparison: 2 IPV‐OPV | ||||||
| Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | № of participants (studies) | Certainty of the evidence (GRADE) | Comments | |
| Risk with IPV(2)‐OPV | Risk with IPV(3)‐OPV | |||||
| Paralytic polio | ‐ | ‐ | ‐ | (0 studies) | ‐ | No data available |
| VAPP cases | ‐ | ‐ | ‐ | (0 studies) | ‐ | No data available |
|
Persons with protective humoral response (Follow‐up 7 months) |
P1: 1000 per 1000 | 980 per 1000 (930 to 1000) | RR 0.98 (0.93 to 1.03) | 137 (1 RCT) | ⊕⊕⊕⊝ Moderatea | ‐ |
| P2: 1000 per 1000 | 1000 per 1000 (970 to 1000) | RR 1.00 (0.97 to 1.03) | 137 (1 RCT) | |||
| P3: 989 per 1000 | 998 per 1000 (959 to 1000) | RR 1.01 (0.97 to 1.05) | 137 (1 RCT) | |||
| Neutralising antibodies | ‐ | ‐ | ‐ | (0 studies) | ‐ | No data available |
| Persons with faecal excretion after OPV challenge | ‐ | ‐ | ‐ | (0 studies) | ‐ | No data available |
| Vaccination coverage | ‐ | ‐ | ‐ | (0 studies) | ‐ | No data available |
| Serious adverse events | ‐ | ‐ | ‐ | (0 studies) | ‐ | No data available |
| *The risk in the intervention group (and its 95% Cl) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio | ||||||
| GRADE Working Group grades of evidence High certainty: we are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect | ||||||
aSerious imprecision: confidence interval limits include clinically important increase or reduction of the effect.